* Amgen And Ucb Announce Positive Top Line results from Phase 3 study evaluating Romosozumab in men with Osteoporosis
The post BRIEF-Amgen -Positive Top Line results from Phase 3 study evaluating Romosozumab in men with Osteoporosis appeared first on NASDAQ.